Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

SECOND BIO LAB CLINICAL LABORATORY

NPI: 1194478867 · SAN GABRIEL, CA 91776 · Clinical Medical Laboratory · NPI assigned 02/01/2022

$160K
Total Medicaid Paid
9,143
Total Claims
6,677
Beneficiaries
13
Codes Billed
2022-03
First Month
2024-10
Last Month

Provider Details

Authorized OfficialORUE-PEREA, GABRIELA (OWNER)
NPI Enumeration Date02/01/2022

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2022 1,747 $72K
2023 2,124 $68K
2024 5,272 $20K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 1,202 633 $85K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 1,150 592 $24K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B 911 331 $18K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 608 296 $13K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 1,195 984 $12K
87481 1,197 990 $4K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 573 572 $2K
87150 456 455 $829.84
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 710 687 $587.25
87640 553 551 $426.67
87653 563 561 $357.11
87498 13 13 $89.83
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets 12 12 $68.98